Keyword: Copaxone

Teva lost a patent appeal for multiple sclerosis blockbuster Copaxone, a drug that has seen a considerable sales decline due to generics.

Teva’s Copaxone has hung on to market share even in the face of oral competitors and generics. But Novartis aims to change that.

Teva is cutting its debt load, but a successful turnaround rests on its new products and late-stage pipeline, analysts say.

Over the last few years, the multiple sclerosis field has been a hotbed for formulary management. But that’s changed a bit in 2018.

Kickbacks whistleblowers reached their "put up or shut up" moment for producing solid evidence—and didn't, Teva says.

Mylan may have cut the list price on its Copaxone copy, but the Israeli drugmaker says it’s still on track to rake in significant 2018 sales.

Thanks to Mylan’s price cut on generic Copaxone, Teva’s going to have to take the price on its branded product down. And it may be wise to start now.

Mylan has slashed its list price on generic Copaxone, and the move has industry watchers scratching their heads.

Teva's restructuring and cost-cutting initiatives are clearly working, but worries about generic competition to MS blockbuster Copaxone are putting pressure on Teva to continue to innovate.

A recently released FDA document shows that Pfizer's troubled fill-finish plant in Kansas was cited for continuing to repeat mistakes already cited by the FDA.